Amanote Research
Register
Sign In
THU0768-HPR Phone Follow-Up Program Enhances Treatment Safety and Drug Concordance on Disease Modifying Anti-Rheumatic Drugs (DMARDS) Therapy for Rheumatology Patients
doi 10.1136/annrheumdis-2017-eular.4421
Full Text
Open PDF
Abstract
Available in
full text
Date
June 1, 2017
Authors
PF Lee
YS Cheung
CK Lam
MC Leung
CM Chan
WL Ng
Publisher
BMJ Publishing Group Ltd and European League Against Rheumatism
Related search
OP0281-HPR Preferences of Patients With Rheumatoid Arthritis Regarding Disease Modifying Anti-Rheumatic Drugs: A Discrete Choice Experiment
Safety, Cost and Effectiveness Issues With Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
PHS30 Health Care Costs in Psoriatic Arthritis (PSA) Patients Newly Initiated on a Biologic Disease-Modifying Anti-Rheumatic Drug (DMARDS) or Methotrexate (MTX)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Effect of Disease-Modifying Anti-Rheumatic Drugs on Bone Structure and Strength in Psoriatic Arthritis Patients
Arthritis Research & Therapy
Patient Preferences in the Choice of Disease Modifying Anti-Rheumatic Drugs
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
THU0094 Factors Associated With Radiographic Remission (RR) in Patients With Rheumatoid Arthritis (RA) While Non-Biologicaldisease Modifying Anti-Rheumatic Drugs (DMARDS) Using
Can Disease-Modifying Anti-Rheumatic Drugs Reduce the Risk of Developing Dementia in Patients With Rheumatoid Arthritis?
Neurotherapeutics
Neurology
Pharmacology
AB0490 Evaluation of Inhibitory Factor of Radiographic Progression by Iguratimod Add-On Therapy in Rheumatoid Arthritis Patients With Inadequate Responses to Disease-Modifying Anti-Rheumatic Drugs
FRI0754-HPR Impact of Corticosteroid Utilization on Biologic Disease-Modifying Antirheumatic Drug Initiation Among Patients With Rheumatoid Arthritis
